Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
The annual Medicare Payment Advisory Commission update to the top 10 list of Medicare Part B prescription drugs has a new number one: Regeneron Pharmaceuticals Inc.’s Eylea.
MedPAC’s June 2017 data book (publicly released at the end of July) lists the macular degeneration therapy as...
Create an account to read this article
Already a subscriber?
Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
